Oxford, AstraZeneca COVID-19 vaccine less effective against S. African variant: Study
British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.
For more coronavirus news, visit our dedicated page.
The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.
“In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant,” an AstraZeneca spokesman said in response to the FT report.
“However, we have not been able to properly ascertain its effect against severe disease and hospitalization given that subjects were predominantly young healthy adults.”
The company said it believed its vaccine could protect against severe disease, given that the neutralizing antibody activity was equivalent to that of other COVID-19 vaccines.
While thousands of individual changes have arisen as the virus mutates into new variants, only a tiny minority are likely to be important or change the virus in an appreciable way, according to the British Medical Journal.
AstraZeneca applies for COVID-19 vaccine approval in Japan
AstraZeneca vaccine explainer: All you need to know after UAE approval
Global COVID-19 vaccinations surpass reported infections: WHO
“Oxford University and AstraZeneca have started adapting the vaccine against this variant and will advance rapidly through clinical development so that it is ready for Autumn delivery should it be needed,” the AstraZeneca spokesman
said.The trial involving more than 2,000 people has not been peer-reviewed, the FT said.
On Friday Oxford said their vaccine has similar efficacy against the British coronavirus variant as it does to the previously circulating variants.
AstraZeneca applies for COVID-19 vaccine approval in JapanDrugmaker AstraZeneca PLC said on Friday it had applied for approval in Japan of its COVID-19 vaccine, making it the second pharmaceutical firm to do ... Coronavirus
EU names industry chief Breton to ramp up vaccine output after delays by AstraZenecaEuropean Union industry commissioner Thierry Breton was put in charge of a new vaccine production task force on Thursday after the EU executive came ... Coronavirus
AstraZeneca, Oxford to produce vaccine effective against COVID-19 variants by AutumnAstraZeneca and Oxford University aim to produce the next generation of COVID-19 vaccines that will protect against variants as soon as the autumn, a ... Coronavirus